Axe Capital Investments

Clear market notes built around the JSE, the rand, and what matters locally.

Axe Capital Trading News shares simple market takes on the stories moving South African shares, the rand, and a handful of major currency pairs.

What you will find here:

1. JSE shares, South African companies, and the local knock-on effects of big market news.

2. The rand, interest rates, and a small group of forex pairs, with USD/ZAR at the centre.

3. Global stories only when they can actually change how a local investor might act.

Latest market stories

Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031

2026-08-01 20:17 • The Motley Fool Positive Axe Cap view: Selective

Eli Lilly is positioned to become the first healthcare company to reach a $2 trillion market cap by 2031, requiring a 12.7% compound annual growth rate. The company's GLP-1 drug portfolio, led by tirzepatide (Mounjaro/Zepbound), is expected to drive strong revenue growth despite increasing competition. Additional growth catalysts include new product launches like Foundayo, pipeline candidates such as retatrutide, and AI-driven cost efficiencies across the organization.

Axe note: Eli Lilly’s growth in weight loss drugs could reshape pharma sector valuations, but South African investors should watch the rand and banking stocks for fallout.

Where Will Micron Stock Be in 2030?

2026-08-01 17:31 • The Motley Fool Neutral Axe Cap view: Selective

Micron Technology reported record quarterly revenue of $41.5 billion with exceptional profitability (84.6% gross margin) and guided for ~$50 billion in the next quarter. However, the analyst cautions that while new customer contracts and AI-focused products (HBM4/HBM4E) may support the current boom longer than past cycles, memory industry history suggests cyclical downturns are inevitable. The base case projects the stock trading between $800-$1,100 by 2030, implying modest returns from current levels.

Axe note: Micron’s stellar revenue and AI-driven product demand look strong but the memory chip cycle always bites back.

Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit?

2026-08-01 17:28 • The Motley Fool Positive Axe Cap view: Selective

The article compares two healthcare-focused ETFs: Fidelity MSCI Health Care Index ETF (FHLC) and iShares U.S. Healthcare ETF (IYH). FHLC is recommended as the better choice due to its significantly lower expense ratio (0.08% vs 0.38%), broader diversification with 334 holdings versus 100, and consistent outperformance across multiple time periods. Over 10 years, a $10,000 investment in FHLC would have yielded approximately $1,900 more than IYH.

Axe note: FHLC beats IYH on fees, diversification, and long-term returns, but what about South African relevance?

See all market stories →

What we follow

We keep the focus on JSE shares, the rand, and the currency moves that matter most to South African investors.

JSE and rand